The 2023 annual update on the Hunter Outcome Survey (HOS) has now been published.
HOS is a large disease registry, sponsored by Takeda, that was set up in 2005 to collect detailed information on patients with mucopolysaccharidosis II (MPS II; Hunter syndrome). HOS has facilitated the collection of data on the signs, symptoms and progression of MPS II and the experiences of patients, whether untreated or treated with idursulfase.
